Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
- PMID: 33803817
- PMCID: PMC8003169
- DOI: 10.3390/jcm10061267
Indications of Peptide Receptor Radionuclide Therapy (PRRT) in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors: An Updated Review
Abstract
Radionuclide therapy for neuroendocrine tumors is a form of systemic radiotherapy that allows the administration of targeted radionuclides into tumor cells that express a large quantity of somatostatin receptors. The two most commonly used radio-peptides for radionuclide therapy in neuroendocrine tumors are 90Y-DOTATOC and 177Lu-DOTATATE. Radio-peptides have been used for several years in the treatment of advanced neuroendocrine tumors. Recently, the randomized Phase III study NETTER-1 compared177Lu-DOTATATE versus high-dose (double-dose) octreotide LAR in patients with metastatic midgut neuroendocrine tumors, and demonstrated its efficacy in this setting. Strong signals in favor of efficiency seem to exist for other tumors, in particular for pancreatic and pulmonary neuroendocrine tumors. This focus on radionuclide therapy in gastroenteropancreatic and pulmonary neuroendocrine tumors addresses the treatment modalities, the validated and potential indications, and the safety of the therapy.
Keywords: PRRT; gastroenteropancreatic tumor; neoplasm metastasis; neuroendocrine tumors; peptide receptor radionuclide therapy; pulmonary tumor.
Conflict of interest statement
R.C. has acted as payed consultant or oral presenter for AAA, Ipsen, Novartis and Keocyt. A.-S.C. has acted as oral presenter for AAA. C.B. has acted as paid consultant of IPSEN. All other authors have no conflict of interest to declare.
Figures
Similar articles
-
Radionuclide Therapy for Neuroendocrine Tumors.Curr Oncol Rep. 2017 Feb;19(2):9. doi: 10.1007/s11912-017-0567-8. Curr Oncol Rep. 2017. PMID: 28220446 Review.
-
Outcome analysis in patients with metastatic gastroenteropancreatic neuroendocrine tumors receiving peptide receptor radionuclide therapy with Lu-177-DOTATATE.J Gastrointest Oncol. 2023 Jun 30;14(3):1204-1217. doi: 10.21037/jgo-22-874. Epub 2023 May 25. J Gastrointest Oncol. 2023. PMID: 37435198 Free PMC article.
-
Peptide receptor radionuclide therapy for patients with advanced pancreatic neuroendocrine tumors.Semin Oncol. 2018 Aug;45(4):236-248. doi: 10.1053/j.seminoncol.2018.08.004. Epub 2018 Oct 24. Semin Oncol. 2018. PMID: 30539715 Review.
-
Peptide Receptor Radionuclide Therapy for Patients With Advanced Lung Carcinoids.Clin Lung Cancer. 2019 May;20(3):e376-e392. doi: 10.1016/j.cllc.2019.02.007. Epub 2019 Mar 1. Clin Lung Cancer. 2019. PMID: 30910575 Review.
-
Guidance on 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy from the Experience of a Single Nuclear Medicine Division.J Nucl Med Technol. 2018 Sep;46(3):237-244. doi: 10.2967/jnmt.118.209148. Epub 2018 Aug 3. J Nucl Med Technol. 2018. PMID: 30076245
Cited by
-
Liver-Directed Locoregional Therapies for Neuroendocrine Liver Metastases: Recent Advances and Management.Curr Oncol. 2024 Apr 5;31(4):2076-2091. doi: 10.3390/curroncol31040154. Curr Oncol. 2024. PMID: 38668057 Free PMC article. Review.
-
[68Ga]Ga-FAP-2286, a novel promising theragnostic approach for PET/CT imaging in patients with various type of metastatic cancers.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1981-1988. doi: 10.1007/s00259-024-06635-8. Epub 2024 Feb 20. Eur J Nucl Med Mol Imaging. 2024. PMID: 38376804
-
Radiopharmaceuticals for Treatment of Adrenocortical Carcinoma.Pharmaceuticals (Basel). 2023 Dec 23;17(1):25. doi: 10.3390/ph17010025. Pharmaceuticals (Basel). 2023. PMID: 38256859 Free PMC article. Review.
-
Targeting the Oxytocin Receptor for Breast Cancer Management: A Niche for Peptide Tracers.J Med Chem. 2024 Feb 8;67(3):1625-1640. doi: 10.1021/acs.jmedchem.3c01089. Epub 2024 Jan 18. J Med Chem. 2024. PMID: 38235665 Free PMC article. Review.
-
Myasthenia gravis as initial presentation of a pancreatic neuroendocrine tumor: A case report.Exp Ther Med. 2023 Sep 25;26(5):523. doi: 10.3892/etm.2023.12222. eCollection 2023 Nov. Exp Ther Med. 2023. PMID: 37854502 Free PMC article.
References
-
- Capello A., Krenning E.P., Breeman W.A.P., Bernard B.F., de Jong M. Peptide receptor radionuclide therapy in vitro using [111In-DTPA0]Octreotide n.d.:8. J. Nucl. Med. 2003;44:98–104. - PubMed
-
- Pool S.E., Krenning E.P., Koning G.A., van Eijck C.H.J., Teunissen J.J.M., Kam B., Valkema R., Kwekkeboom D.J., de Jong M., Valkema R., et al. Preclinical and clinical studies of peptide receptor radionuclide therapy. Semin. Nucl. Med. 2010;40:209–218. doi: 10.1053/j.semnuclmed.2009.12.001. - DOI - PubMed
-
- Kratochwil C., Stefanova M., Mavriopoulou E., Holland-Letz T., Dimitrakopoulou-Strauss A., Afshar-Oromieh A., Mier W., Haberkorn U., Giesel F.L. SUV of [68Ga]DOTATOC-PET/CT predicts response probability of PRRT in neuroendocrine tumors. Mol. Imaging Biol. 2015;17:313–318. doi: 10.1007/s11307-014-0795-3. - DOI - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous